CAS 1703788-21-9

Methanone, cyclopropyl[5-[[4-[4-[[(4S)-4-hydroxy-2-isoxazolidinyl]methyl]-3-methyl-1H-pyrazol-1-yl]-2-pyrimidinyl]amino]-1-methyl-1H-indol-3-yl]-

Description:

Methanone, cyclopropyl[5-[[4-[4-[[(4S)-4-hydroxy-2-isoxazolidinyl]methyl]-3-methyl-1H-pyrazol-1-yl]-2-pyrimidinyl]amino]-1-methyl-1H-indol-3-yl]- is a complex organic compound characterized by its intricate molecular structure, which includes multiple functional groups such as isoxazolidine, pyrazole, and pyrimidine. This compound is likely to exhibit specific biological activity due to its diverse functional groups, which may contribute to interactions with biological targets. The presence of a cyclopropyl group suggests potential strain and reactivity, while the hydroxyl group may enhance solubility and hydrogen bonding capabilities. The compound's molecular weight, solubility, and stability would depend on its specific structural features and the arrangement of its substituents. As a synthetic compound, it may be of interest in medicinal chemistry for its potential therapeutic applications, particularly in the development of novel pharmaceuticals. Further studies would be necessary to elucidate its full chemical properties and biological effects.

Formula: C₂₅H₂₇N₇O₃

Synonyms:

• Cevidoplenib
• Cyclopropyl[5-[[4-[4-[[(4S)-4-hydroxy-2-isoxazolidinyl]methyl]-3-methyl-1H-pyrazol-1-yl]-2-pyrimidinyl]amino]-1-methyl-1H-indol-3-yl]methanone
• Methanone, cyclopropyl[5-[[4-[4-[[(4S)-4-hydroxy-2-isoxazolidinyl]methyl]-3-methyl-1H-pyrazol-1-yl]-2-pyrimidinyl]amino]-1-methyl-1H-indol-3-yl]-

Cevidoplenib

CAS: 1703788-21-9

Cevidoplenib is a small molecule inhibitor of the receptor tyrosine kinase RET, which is associated with a variety of cancers. It binds to the active site of RET, preventing activation and causing RET to be degraded. Cevidoplenib inhibits the phosphorylation of tyrosine residues on RET, thereby blocking RET-mediated signaling cascades. This inhibition leads to decreased cell proliferation and survival in vitro and in vivo. Cevidoplenib is currently in phase II clinical trials for patients with thyroid cancer or medullary thyroid carcinoma.

Formula: C₂₅H₂₇N₇O₃

Purity: Min. 95%

Molecular weight: 473.5 g/mol

Ref: 3D-DTC78821